Kurveundersøgelse af Entrectinib (RXDX-101) til behandling af patienter med solide tumorer, der rummer NTRK 1/2/3 (Trk A/B/C), ROS1 eller ALK genrearrangementer (fusioner) (STARTRK-2)
Et åbent, multicenter, globalt fase 2-basketstudie af entrectinib til behandling af patienter med lokalt avancerede eller metastatiske solide tumorer, der rummer NTRK1/2/3-, ROS1- eller ALK-genomlægninger
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
Studieoversigt
Status
Status
Betingelser
Betingelser
- Melanom
- Nyrecellekarcinom
- Voksen fast tumor
- Brystkræft
- Neoplasmer i hoved og hals
- Kolorektal cancer
- Kræft i bugspytkirtlen
- Livmoderhalskræft
- Ikke-småcellet lungekræft
- Neuroendokrine tumorer
- Lymfom, storcellet, anaplastisk
- Cholangiocarcinom
- Papillær skjoldbruskkirtelkræft
- Sarkomer
- Spytkirtelkræft
- Primære hjernetumorer
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Udvidet adgang
Udvidet adgang
Ikke længere tilgængelig
- Tilgængelig: Udvidet adgang er i øjeblikket tilgængelig for denne forsøgsbehandling, og patienter, der ikke er deltagere i den kliniske undersøgelse, kan muligvis få adgang til lægemidlet, det biologiske eller medicinske udstyr undersøgt.
- Ikke længere tilgængelig: Udvidet adgang var tilgængelig for denne intervention tidligere, men er ikke tilgængelig i øjeblikket og vil ikke være tilgængelig i fremtiden.
- Midlertidigt ikke tilgængelig: Udvidet adgang er i øjeblikket ikke tilgængelig for denne intervention, men forventes at være tilgængelig i fremtiden.
- Godkendt til markedsføring: Interventionen er blevet godkendt af U.S. Food and Drug Administration til brug for offentligheden.
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Liverpool, New South Wales, Australien, 2170
- Liverpool Hospital
-
Newcastle, New South Wales, Australien, 2305
- Newcastle Private Hospital
-
-
South Australia
-
Bedford Park, South Australia, Australien, 5042
- Flinders Medical Centre
-
-
Victoria
-
Heidelberg, Victoria, Australien, 3084
- Austin Health
-
-
-
-
-
Edegem, Belgien, 2650
- Pharmacy
-
-
-
-
-
Cambridge, Det Forenede Kongerige, CB2 0QQ
- Addenbrookes Hospital
-
London, Det Forenede Kongerige, W1G 6AD
- Sarah Cannon Research Institute
-
Manchester, Det Forenede Kongerige, M20 4BX
- The Christie
-
-
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85054
- Mayo Clinic
-
Phoenix, Arizona, Forenede Stater, 85013
- Dignity Health St Joseph's Hospital and Medical Center
-
-
California
-
Duarte, California, Forenede Stater, 91010
- City of Hope Cancer Center
-
Duarte, California, Forenede Stater, 91010
- City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services
-
La Jolla, California, Forenede Stater, 92037
- Scripps Clinic
-
La Jolla, California, Forenede Stater, 92093
- University of California San Diego Moores Cancer Center
-
Los Angeles, California, Forenede Stater, 90027
- Southern California Kaiser Permanente
-
Orange, California, Forenede Stater, 92868
- Univ Of California Irvine College Of Medicine
-
San Francisco, California, Forenede Stater, 94158
- UCSF Mission Bay
-
San Francisco, California, Forenede Stater, 94115
- UCSF Mount Zion Medical Ctr
-
Santa Monica, California, Forenede Stater, 90403
- Sarcoma Oncology Center
-
Santa Monica, California, Forenede Stater, 90403
- Sarcoma Oncology Research Center LLC
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- University of Colorado Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 6519
- Yale University
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20007
- Georgetown University Medical Center Lombardi Cancer Center
-
-
Florida
-
Sarasota, Florida, Forenede Stater, 34232
- Florida Cancer Specialists - Sarasota
-
Tampa, Florida, Forenede Stater, 33612-9497
- Moffitt Cancer Center
-
Tampa, Florida, Forenede Stater, 33612-9497
- H. Lee Moffitt Cancer Center and Research Inst.
-
-
Georgia
-
Athens, Georgia, Forenede Stater, 30607
- University Cancer & Blood Center, LLC
-
Atlanta, Georgia, Forenede Stater, 30322
- Winship Cancer Institute
-
Newnan, Georgia, Forenede Stater, 30265
- Southeastern Regional Medical Center, Inc.
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern University
-
Park Ridge, Illinois, Forenede Stater, 60068
- Advocate Medical Group - Park Ridge, Luther Lane - Oncology
-
Zion, Illinois, Forenede Stater, 60099
- Midwestern Regional Medical Center
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21237
- Weinberg Cancer Institution at Franklin Square
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Forenede Stater, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Forenede Stater, 02215
- Dana Farber Cancer Institute
-
Boston, Massachusetts, Forenede Stater, 02114
- Massachusetts General Hosp CAR
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Forenede Stater, 48201
- Karmanos Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55455
- Regents of the University of Minnesota
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63128
- Washington University
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89169
- Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley
-
-
New York
-
East Setauket, New York, Forenede Stater, 11733
- North Shore Hem Onc Associates
-
New York, New York, Forenede Stater, 10022
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28204
- Levine Cancer Institute
-
Charlotte, North Carolina, Forenede Stater, 28204
- Atrium Health Levine Cancer Institute
-
Durham, North Carolina, Forenede Stater, 27710
- Duke Cancer Institute
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43210
- Ohio State University
-
-
Oklahoma
-
Tulsa, Oklahoma, Forenede Stater, 74133
- Cancer Treatment Centers of America
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239-3098
- Oregon Health & Science University
-
Portland, Oregon, Forenede Stater, 97239
- Oregon Health & Science Univ
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75230
- Mary Crowley Medical Research Center
-
Temple, Texas, Forenede Stater, 76508
- Baylor Scott & White Health
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Virginia Cancer Specialists, PC
-
Norfolk, Virginia, Forenede Stater, 23502
- Virginia Oncology Associates - Hampton
-
-
-
-
-
Angers, Frankrig, 49055
- Institut de Cancerologie de l Ouest
-
Lyon, Frankrig, 69373
- Centre Leon Berard
-
Marseille, Frankrig, 13915
- Hôpital Nord - AP-HM Marseille#
-
Marseille, Frankrig, 13385
- Hôpital de la Timone
-
Montpellier, Frankrig, 34090
- Institut de Recherche en Cancérologie de Montpellier
-
Toulouse, Frankrig, 31059
- Institut Claudius Regaud
-
Villejuif, Frankrig, 94805
- Institut Gustave Roussy
-
-
-
-
-
Leiden, Holland, 2333 ZA
- Leids Universitair Medisch Centrum
-
-
-
-
-
Hong Kong, Hong Kong
- The University of Hong Kong
-
Hong Kong, Hong Kong
- Princess Margaret Hospital
-
Kowloon, Hong Kong
- Queen Elizabeth Hospital
-
Shatin, Hong Kong, 123456
- The Chinese University of Hong Kong
-
-
-
-
Campania
-
Naples, Campania, Italien, 80131
- Seconda Università degli Studi di Napoli
-
-
Lazio
-
Rome, Lazio, Italien, 128
- Università Campus Bio-Medico di Roma
-
-
Lombardy
-
Milan, Lombardy, Italien, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan, Lombardy, Italien, 20162
- Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda)
-
-
Tuscany
-
Pisa, Tuscany, Italien, 56126
- Azienda Ospedaliero Universitaria Pisana
-
-
Umbria
-
Perugia, Umbria, Italien, 6132
- Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia
-
-
Veneto
-
Padova, Veneto, Italien, 35128
- IOV - Istituto Oncologico Veneto - IRCCS
-
-
-
-
-
Aichi, Japan, 464-8681
- Aichi Cancer Center Hospital
-
Chūō, Japan, 104-0045
- National Cancer Center Hospital
-
Hyōgo, Japan, 673-8558
- Hyogo Cancer Center, Dept of Respiratory Medicine
-
Matsuyama, Japan, 791-0280
- NHO Shikoku Cancer Center
-
Miyagi, Japan, 981-1293
- Miyagi Cancer Center
-
Niigata, Japan, 951-8566
- Niigata Cancer Center Hospital
-
Osaka, Japan, 589-8511
- Kindai University Hospital
-
Osaka, Japan, 534-0021
- Osaka City General Hospital
-
Shizuoka, Japan, 411-8777
- Shizuoka Cancer Center
-
-
-
-
-
Beijing, Kina, 100142
- Beijing Cancer Hospital
-
Guangzhou, Kina, 528400
- Cancer Center of Guangzhou Medical University
-
Hangzhou, Kina, 310022
- Zhejiang Cancer Hospital
-
Shanghai, Kina, 200120
- Fudan University Shanghai Cancer Center
-
Shanghai, Kina, 200030
- Shanghai chest hospital
-
Shenzhen, Kina, 510852
- Shenzhen People's Hospital
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina, 150081
- Harbin Medical University Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, Kina, 430023
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Sichuan Cancer Hospital
-
-
-
-
-
Gliwice, Polen, 44-101
- Centrum Onkologii-Instytut im.M.Sklodowskiej Curie
-
Późna, Polen, 60-569
- Szpital Kliniczny Przemienienia Panskiego Uni. Medycznego im. Karola Marcinkowskiego
-
-
-
-
-
Singapore, Singapore, 119228
- National University Hospital
-
Singapore, Singapore, 168583
- National Cancer Centre Singapore
-
-
-
-
-
Barcelona, Spanien, 08035
- Vall d?Hebron Institute of Oncology (VHIO), Barcelona
-
Madrid, Spanien, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Spanien, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spanien, 28046
- Hospital Universitario La Paz
-
Madrid, Spanien, 28040
- Hospital Universitario Clínico San Carlos
-
Málaga, Spanien, 29010
- Hospital Clinico Universitario Virgen de la Victoria
-
Seville, Spanien, 41013
- Hospital Universitario Virgen del Rocio
-
-
Madrid
-
Fuenlabrada, Madrid, Spanien, 28942
- Centro Nacional de Investigaciones Oncológicas(CNIO)
-
-
-
-
-
Seoul, Sydkorea, 03080
- Seoul National University Hospital
-
Seoul, Sydkorea, 06351
- Samsung Medical Center
-
Seoul, Sydkorea, 05505
- Asan Medical Center.
-
Seoul, Sydkorea, 120-752
- Severance Hospital, Yonsei University Health System
-
-
-
-
-
Tainan, Taiwan, 70457
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 00100
- National Taiwan University Hospital
-
-
-
-
-
Berlin, Tyskland, 13125
- Evang. Lungenklinik Berlin Klinik für Pneumologie
-
Cologne, Tyskland, 50937
- Universitaetsklinikum Koeln
-
Göttingen, Tyskland, 37075
- Universitaetsmedizin Goettingen
-
Heidelberg, Tyskland, 69120
- NCT Uniklinikum Heidelberg
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement
-
For patients enrolled via local molecular testing, an archival or fresh tumor tissue (unless medically contraindicated) is required to be submitted for independent central molecular testing at Ignyta's CLIA laboratory post-enrollment
-
Measurable or evaluable disease
-
Patients with CNS involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously-treated and controlled, are allowed
-
Prior anticancer therapy is allowed (excluding approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements)
- Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are prohibited.
-
At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior chemotherapy or small molecule targeted therapy
-
At least 4 weeks must have elapsed since completion of antibody-directed therapy
-
Prior radiotherapy is allowed if more than 14 days have elapsed since the end of treatment
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and minimum life expectancy of 4 weeks
-
Adequate organ function as defined per protocol
-
Ability to swallow entrectinib intact
-
Other protocol specified criteria
Exclusion Criteria:
-
Current participation in another therapeutic clinical trial
-
Prior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements
- Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are prohibited.
-
History of other previous cancer that would interfere with the determination of safety or efficacy
-
Familial or personal history of congenital bone disorders, or bone metabolism alterations
-
Incomplete recovery from any surgery
-
History of recent (within the past 3 months) symptomatic congestive heart failure or ejection fraction ≤50% observed during screening for the study
-
History of non-pharmacologically induced prolonged QTc interval
-
History of additional risk factors for torsades de pointes
-
Peripheral neuropathy Grade ≥ 2
-
Known active infections
-
Active gastrointestinal disease or other malabsorption syndromes
-
Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis
-
Other protocol specified criteria
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: NTRK1/2/3-rearranged NSCLC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andre navne:
|
|
Eksperimentel: ROS1-rearranged NSCLC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andre navne:
|
|
Eksperimentel: ALK- or ROS1-rearranged NSCLC
with CNS-only progression previously treated with crizotinib (NOTE: The ALK-rearranged portion of this arm is now closed to enrollment.) Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andre navne:
|
|
Eksperimentel: NTRK/1/2/3-rearranged mCRC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andre navne:
|
|
Eksperimentel: ROS1-rearranged mCRC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andre navne:
|
|
Eksperimentel: ALK-rearranged mCRC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andre navne:
|
|
Eksperimentel: NTRK1/2/3-rearranged other solid tumor
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andre navne:
|
|
Eksperimentel: ROS1-rearranged other solid tumor
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andre navne:
|
|
Eksperimentel: ALK-rearranged other solid tumor
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate
Tidsramme: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RECIST v1.1 |
Approximately 24 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Duration of Response
Tidsramme: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RECIST v1.1 |
Approximately 24 months
|
|
Time to Response
Tidsramme: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RECIST v1.1 |
Approximately 24 months
|
|
Clinical Benefit Rate
Tidsramme: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RECIST v1.1 |
Approximately 24 months
|
|
Intracranial Tumor Response
Tidsramme: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RANO or RANO-BM, as applicable |
Approximately 24 months
|
|
CNS Progression-free Survival
Tidsramme: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RANO or RANO-BM, as applicable |
Approximately 24 months
|
|
Progression-free Survival
Tidsramme: Approximately 30 months
|
Assessed by Kaplan-Meier method |
Approximately 30 months
|
|
Overall Survival
Tidsramme: Approximately 36 months
|
Assessed by Kaplan-Meier method |
Approximately 36 months
|
|
Population PK
Tidsramme: Approximately 24 months
|
Assessed by Kaplan-Meier method |
Approximately 24 months
|
|
Adverse Events
Tidsramme: Approximately 36 months
|
Type, incidence, severity, timing, seriousness, and relatedness of adverse events and laboratory abnormalities, graded by the NCI CTCAE |
Approximately 36 months
|
|
Quality of Life
Tidsramme: Approximately 24 months
|
Assessed with the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and the Euro-QoL Group EQ-5D. NSCLC and mCRC patients will complete the lung cancer and colorectal cancer specific modules, QLQ-LC13 and QLQ-CR29, respectively |
Approximately 24 months
|
|
Bone Growth and Bone Mineral Density
Tidsramme: Approximately 30 months
|
Assessed with DHA scans |
Approximately 30 months
|
|
Bone Biomarkers
Tidsramme: Approximately 30 months
|
Measured by blood |
Approximately 30 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Clinical Trials, Hoffmann-La Roche
Publikationer og nyttige links
Generelle publikationer
- Sullivan WG, Hatswell AJ. Letter re: 'Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications'. ESMO Open. 2021 Dec;6(6):100282. doi: 10.1016/j.esmoop.2021.100282. Epub 2021 Oct 28. No abstract available.
- Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 Apr 10;39(11):1253-1263. doi: 10.1200/JCO.20.03025. Epub 2021 Mar 1.
- Sigal D, Tartar M, Xavier M, Bao F, Foley P, Luo D, Christiansen J, Hornby Z, Maneval EC, Multani P. Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer. J Natl Compr Canc Netw. 2017 Nov;15(11):1317-1322. doi: 10.6004/jnccn.2017.7029.
- Doebele RC, Perez L, Trinh H, Martinec M, Martina R, Riehl T, Krebs MG, Meropol NJ, Wong WB, Crane G. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. J Comp Eff Res. 2021 Dec;10(17):1271-1282. doi: 10.2217/cer-2021-0131. Epub 2021 Aug 24.
- Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11.
- Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.
- Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22.
- Choudhury NJ, Jun Woo H, Chen M, Shah R, Donoghue M, Berger M, Drilon A. Serial Cell-Free DNA Sequencing in ROS1 Fusion-Positive Lung Cancers During Treatment With Entrectinib. JCO Precis Oncol. 2024 Jun;8:e2300721. doi: 10.1200/PO.23.00721.
- Yokota T, Yukino H, Doi M, Ohori H. Real-world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6-NTRK3 positive metastatic salivary secretory carcinoma: A case series. Head Neck. 2023 May;45(5):E10-E15. doi: 10.1002/hed.27346. Epub 2023 Mar 16.
- Ajani JA, D'Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, Enzler T, Gerdes H, Gibson MK, Grierson P, Gupta G, Hofstetter WL, Ilson DH, Jalal S, Kim S, Kleinberg LR, Klempner S, Lacy J, Lee B, Licciardi F, Lloyd S, Ly QP, Matsukuma K, McNamara M, Merkow RP, Miller AM, Mukherjee S, Mulcahy MF, Perry KA, Pimiento JM, Reddi DM, Reznik S, Roses RE, Strong VE, Su S, Uboha N, Wainberg ZA, Willett CG, Woo Y, Yoon HH, McMillian NR, Stein M. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 May;23(5):169-191. doi: 10.6004/jnccn.2025.0022.
- Yu Y, Fan Y, Dong X, Li J, Yu Y, Zhao J, Tao S, Chen Y, Chen M, Liu Y, Xu J, Zhu Q, Hu X, Lu S. Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison. Lung Cancer. 2024 Dec;198:108018. doi: 10.1016/j.lungcan.2024.108018. Epub 2024 Nov 10.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- Kolorektal cancer
- Ikke-småcellet lungekræft
- Brystkræft
- Livmoderhalskræft
- Melanom
- Kræft i bugspytkirtlen
- Cholangiocarcinom
- Neuroendokrine tumorer
- Kurv undersøgelse
- Nyrecellekræft
- Papillær skjoldbruskkirtelkræft
- ROS1
- ALK
- Primære hjernetumorer
- Sarkomer
- Entrectinib
- RXDX-101
- TrkA
- TrkB
- TrkC
- NTRK1
- NTRK2
- NTRK3
- Trk Fusions
- NTRK-genomlægninger
- ROS1 fusioner
- ROS1-genomlægninger
- ALK Fusions
- ALK-genomlægninger
- Spytkirtelkræft
- Hoved- og nakkekræft
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Sygdomme i det endokrine system
- Mundsygdomme
- Stomatognatiske sygdomme
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Tarmsygdomme
- Sygdomme i immunsystemet
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Kønssygdomme, kvindelige
- Lungesygdomme
- Thyroidneoplasmer
- Neoplasmer i endokrine kirtler
- Pancreassygdomme
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Tyktarmssygdomme
- Lungeneoplasmer
- Ovariesygdomme
- Adnexale sygdomme
- Genitale neoplasmer, kvindelige
- Gonadale lidelser
- Hudsygdomme
- Brystsygdomme
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Urologiske neoplasmer
- Karcinom
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Lymfom
- Neoplasmer i nervesystemet
- Nyre-neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Spytkirtelsygdomme
- Neoplasmer, bindevæv og blødt væv
- Nevi og melanomer
- Neoplasmer i huden
- Neoplasmer i centralnervesystemet
- Skjoldbruskkirtelsygdomme
- Adenocarcinom, papillært
- Mundens neoplasmer
- Lymfom, T-celle
- Hud- og bindevævssygdomme
- Hemiske og lymfatiske sygdomme
- Kræft i skjoldbruskkirtlen, papillær
- Kolorektale neoplasmer
- Ovariale neoplasmer
- Brystneoplasmer
- Bugspytkirtel neoplasmer
- Karcinom, nyrecelle
- Karcinom, ikke-småcellet lunge
- Cholangiocarcinom
- Neoplasmer i hoved og hals
- Neuroendokrine tumorer
- Melanom
- Sarkom
- Lymfom, storcellet, anaplastisk
- Neoplasmer i hjernen
- Spytkirtelneoplasmer
- entrektinib
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- RXDX-101-02
- 2015-003385-84 (EudraCT nummer)
- GO40782 (Anden identifikator: Hoffman-La Roche)
- 2023 (U.S. NIH-bevilling/kontrakt)
- 2015 (U.S. NIH-bevilling/kontrakt)
- 2023-505034-10-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .